HOMEPRODUCTSCOMPANYCONTACTFAQResearchDictionaryPharmaSign Up FREE or Login

Afelimomab led to a modest mortality benefit in patients with severe sepsis and elevated interleukin-6 levels.

AuthorsEliseo Rondon, Ramesh Venkataraman
JournalCritical care (London, England) (Crit Care) Vol. 9 Issue 5 Pg. E20 (Aug 05 2005) ISSN: 1466-609X [Electronic] England
PMID16277704 (Publication Type: Clinical Trial, Phase III, Journal Article, Multicenter Study, Randomized Controlled Trial)
Chemical References
  • Antibodies, Monoclonal
  • Interleukin-6
  • Tumor Necrosis Factor-alpha
  • afelimomab
Topics
  • Antibodies, Monoclonal (therapeutic use)
  • Cause of Death
  • Epidemiologic Methods
  • Humans
  • Interleukin-6 (antagonists & inhibitors, blood)
  • Sepsis (blood, drug therapy, mortality)
  • Tumor Necrosis Factor-alpha (drug effects)

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.
Realize the full power of the drug-disease research graph!


Choose Username:
Email:
Password:
Verify Password:
Enter Code Shown: